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ABSTRACT
DESCRIPTIVE EPIDEMIOLOGY OF ADULT LIPOSARCOMA: A POPULATIONBASED STUDY USING SEER AND THE COMBINED SEER/NPCR DATABASES,
2001-2016
SUZANNE BOCK
November 12, 2019

INTRODUCTION:
Rare cancers, affecting 1 in 5 cancer patients, disproportionally contribute to cancer mortality.
This research focused on liposarcoma, an understudied rare cancer with unknown risk factors
and limited treatment options.

METHODS:
Liposarcoma incident cases were identified from the Surveillance, Epidemiology, and End
Result (SEER) program and the combined SEER-National Program of Cancer Registries
(CNPCR) for 2001-2016. Incidence rates (age-adjusted and age-specific) and 5-year survival
were calculated using SEER*stat. Time trends were determined using Joinpoint.

RESULTS:
SEER liposarcoma cases represented ~30% (n=11,162) of the nationwide pool (n=37,499).
Males accounted for ~60% of the cases, 82% cases were identified among whites. Age-adjusted
incidence was greater among males vs. females and whites vs. blacks, whereas survival did not
differ by sex and race (~80%). The dedifferentiated (57.2%), pleomorphic (64.1%) and
retroperitoneal (63.9%) tumors had the worse survival. Liposarcoma rates increased nationwide

by 19% in 2001-2016, with the annual percent increase (APC) of 1.43% (95% CI: 1.12-1.47).
The APC was greater for males vs. females (1.67% vs. 0.89%) and retroperitoneal vs. extremity
tumors (1.96% vs. 0.58%). The SEER generally overestimated the rates and time trends
compared to nationwide data.

CONCLUSIONS:
The comprehensive description of liposarcoma epidemiology reveals increasing incidence of this
understudied rare cancer, with greater increases among males, the high-risk subgroup and
retroperitoneal tumors, the low-survival subgroup. The time trends suggest an environmental
component, which if discovered, may help to prevent liposarcoma. Differences between SEER
and CNPCR findings emphasize the need for nationwide cancer surveillance.
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CHAPTER I
INTRODUCTION
1.1

Rare Diseases
According to the National Center for Advancing Translational Sciences (2017), a rare

disease in the United States is defined as a disorder that affects less than 200,000 people.
Internationally this accounts for as many as 7,000 different diseases (National Center for
Advancing Translational Sciences, 2017). While each rare disease may only affect a relatively
small number of individuals, the sum of all these diseases has a far-reaching impact on population
health. The National Organization of Rare Disorders (2016) estimates that up to 30 million people
or 10 percent of the U.S. population have a rare disease. Globally, this translates to 350 million
people (Global Genes, n.d.). Even though rare diseases affect many people worldwide, there is a
lack of attention towards the diagnosis and treatment of these uncommon disorders. Often
overlooked by pharmaceutical companies, researchers, and the scientific community, a new name
emerged for these forgotten diseases, “orphan” (Bolignano & Pisano, 2016). Intending to address
the public health issues surrounding orphan diseases, in 1983 Congress passed the Orphan Drug
Act. This act gave pharmaceutical companies financial incentives to plan and develop drugs for
these forgotten diseases (National Center for Advancing Translational Sciences, 2017). However,
to date, there is still more to be done to raise awareness towards these diseases.
The collective impact of rare diseases is far-reaching. The National Organization of Rare
Disorders (2016) claims that “there are more Americans who live with a rare disease than all of
those who have either HIV, heart disease, or stroke” (p. 2). Despite the sizable number of people
affected, rare diseases still lack the attention and funding of more common disorders. Rare
diseases can also be challenging to identify. Many times, insufficient knowledge about the 7,000
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different rare diseases leads to delays in getting a proper diagnosis. The average time from
symptom onset to a correct diagnosis for someone with a rare disorder is six years (Blöß et al.,
2017). During this time, patients see many doctors and specialists trying to uncover the source of
their symptoms. Even when a doctor is familiar with the disease, heterogeneity of rare diseases
can complicate matters (Ronicke et al., 2019). Low incidence combined with many different
subtypes for the same disease will often delay diagnosis (Ronicke et al., 2019).
Once a person is diagnosed, treatment for rare diseases is extremely limited. Given the
small number of cases associated with rare diseases, animal models and small sample sizes make
the development of therapeutic options expensive and difficult (Palmer & Pryde, 2014).
According to the National Organization of Rare Disorders (2016), it is estimated that only 5% of
all rare diseases have corresponding therapy. Thus, rare diseases burden patients, doctors, and
health systems with their lack of treatment options, high costs of existing treatment, and frequent
misdiagnosis.
1.2

Rare Cancers
Rare cancers share many of the problems associated with rare diseases such as insufficient

knowledge, lack of funding, and limited treatment options. As with rare diseases, rare cancers are
also widespread throughout the world. In the European Union, estimates of rare cancers are
calculated at 108 new cases per 100,000 people, or 22% of all new annual cancer diagnoses (Gatta
et al., 2011). Similarly, in the United States, 20% of all new cancer diagnoses are considered rare
(DeSantis, Kramer, & Jemal, 2017). These numbers constitute a substantial proportion of all new
cancer diagnoses. Unlike rare diseases, however, rare cancers are often fatal. Population-based
research reveals the stark statistics of the rare cancer burden. The five-year relative survival for
rare cancers from 2000 to 20007 verses more common cancers in the European Union was 49%
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vs. 64% (Gatta et al., 2011). Similarly, in the United States, compared to more common cancers,
rare cancer 5-year relative survival among males was (55% vs. 75%) and among females was
(60% vs. 74%) (DeSantis, Kramer, & Jemal, 2017).
Heterogeneity of rare cancers further complicates the development of evidence-based
guidelines of care. For example, even though sarcomas represent 1% of all adult malignant tumors,
included in that 1%, are over 70 different subtypes (Mathoulin-Pelissier & Pritchard-Jones, 2019).
Randomized controlled trials for these distinct morphologies are often underpowered, leaving
many questions of treatment and care unanswered. Hence, all of the above-mentioned issues –
misdiagnosis, limited treatment options, and lack of viable prevention measures – are especially
serious for rare cancers, making it one of the most dramatic unresolved public health problems.
1.3

Liposarcoma
Liposarcoma is a rare cancer that forms from mesenchymal cells in the body. It can be

found anywhere on the body but is most commonly found in the extremities and the
retroperitoneum (Barbetakis et al., 2007). Although liposarcoma is a rare cancer, it is the most
common of all sarcomas, accounting for 20% of all mesenchymal tumors (Schwartz, 2019). In
2013, the World Health Organization issued a reclassification of soft tissue sarcomas that redefined
liposarcoma into 4 major histological subgroups: atypical lipomatous tumors/well-differentiated
liposarcoma, dedifferentiated liposarcoma, myxoid liposarcoma, and pleomorphic liposarcoma (Jo
& Fletcher, 2014). This new classification system not only takes into consideration the distinct
morphology, but also the genetic make-up of the tumor, helping researchers to determine patterns
of disease and treatment options (Blay, 2018).
1.4

SEER and NPCR databases
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One way that cancer researchers track cancer incidence and survival statistics is through
The Surveillance, Epidemiology, and End Result (SEER) program. The SEER database provides
data from 18 registries across the United States, representing approximately 27.8% of the
population (SEER, n.d). SEER has been a popular source for population-based cancer-related
research for years. Just recently, however, the National Program of Cancer Registries (NPCR)
publicly released data that covers 46 states and 97% of the United States Population (Centers for
Disease Control and Prevention, n.d.). Combined with the SEER database, this dataset provides
cancer statistics covering 100% of the United States population (Centers for Disease Control and
Prevention, n.d.). The combined dataset allows researchers to have a larger covered population
and thus, a better representation of cancer surveillance in the United States. While both data
sources provide useful information, each has specific advantages. Although the SEER database
only represents approximately 27.8% of the population, its key advantage is that it contains more
detailed information regarding tumor characteristics and estimates of survival. The primary
benefit of the combined NPCR (CNPCR), on the other hand, is the broader representation of cancer
in the U.S., despite having a more limited number of variables in the dataset.
1.5

Gaps and Purpose of Study
The population-based research of liposarcoma in the U.S. is limited. Previously published

analyses of liposarcoma incidence focused on histology (Wu, Qian, & Jin, 2019), targeted therapy
(Tseng, et al., 2011) and the relationship between survival and tumor location or treatment (Smith
et al., 2012; Gerry, Fox, Spruill, & Lentsch, 2014). This analysis fills the gaps in the literature by
not only including the latest and most comprehensive data available, but also by focusing on
liposarcoma incidence trends over time.
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1.6

Research Questions
This analysis begins by examining the distribution and incidence rates of liposarcoma cases

by demographic and tumor characteristics. Age-specific incidence rates and time trends of
liposarcoma are examined in the mostly unknown etiology of this rare cancer. Next, I compare
the nation-wide estimates (combined NPCR and SEER) with those derived from SEER. Lastly, I
delve further into liposarcoma by examining SEER only estimates through grade, size, stage, and
survival analysis.
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CHAPTER 2
REVIEW OF LITERATURE
2.1

Liposarcoma and Gender
The association between gender and liposarcoma has been documented in several

lipomatous tumor studies.

Dalal, Kattan, Antonescu, Brennan, & Singer, (2006) collected

liposarcoma data from Memorial Sloan-Kettering Cancer Center from 1982 to 2005. During that
time period, 801 patients were diagnosed with primary liposarcoma of the extremity, trunk, or
retroperitoneum. Of those 801 patients, 69% (n=471), were men. Likewise, Hoffman et al. (2007)
investigated localized and metastatic myxoid/round cell liposarcoma at MD Anderson cancer
center from 1990 to 2010, and their results show, that 119 of the 207 people (57%) identified as
having liposarcoma, were men. Vos et al. (2018) collected data on patients diagnosed with
liposarcoma extremity cases from 1986 to 2015 at the Erasmus MC Cancer Institute (Rotterdam),
and from 1990 and 2015 at the Maria Skłodowska-Curie Institute-Oncology Center (Warsaw).
They also found that the majority (51%) of the cases were male.
Higher incident liposarcoma rates among males were not limited to small research
institutions. Broader analysis also found this association between liposarcoma incidence and male
sex. The National Cancer Intelligence Network examined liposarcoma incidence rates in England
from 2007 to 2009, and they found twice greater liposarcoma rates among males vs. females
(2013). Similarly, SEER estimates of liposarcoma data collected from 1978-2001, confirmed the
majority (59%) of liposarcoma cases identified were males (Toro et al., 2006).
Research regarding survival estimates between men and women has been mixed. Smith et
al., showed no sex differences among well-differentiated liposarcoma in the overall and diseasespecific survival (2012). However, another study, which examined survival among patients with
extremity myxoid liposarcomas, showed males as being a negative survival predictor (Wu, Qian,
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& Jin, 2019). For all cancer types overall, the increased cancer risk and poor survival among males
have been established by population-based data (Radkiewicz, Johansson, Dickman, Lambe, &
Edgren, 2017; Afshar et al., 2018; Ellison, 2016). Thus, more research is necessary to help
elucidate the association between gender and liposarcoma.
2.2

Liposarcoma and Race
Research into liposarcoma and race has been clear, with the majority of incident cases

found among whites. For example, in a study where researchers used 1973-2009 SEER data to
compare head and neck liposarcoma cases to those liposarcoma cases found on other parts of the
body, Gerry, Fox, Spruill, and Lentsch (2003), found that 82% of the 318 head and neck
liposarcoma cases and 85% of the 9,485 other liposarcoma cases were of white ethnicity. Smith et
al. (2011), also used the SEER database to identify 1,266 cases of well-differentiated liposarcoma
from 1988-2004. Their results show that the majority, or 72%, of the patients were white. Another
study that examined well-differentiated liposarcoma patient characteristics found that 79% of their
62 patients were categorized as being white (Keung et al., 2018). Lastly, Patil and Chamberlain
concurred with other research, finding that 1,117 or 82% of the 1,358 patients diagnosed with
liposarcoma were white.
2.3

Liposarcoma and Histological Type
Histological type plays an important role in determining the extent of disease, treatment

options, and survival statistics of liposarcoma. As mentioned earlier, following the WHO’s
reclassification, liposarcoma is categorized by four distinct subtypes: atypical lipomatous
tumors/well-differentiated liposarcoma, dedifferentiated liposarcoma, myxoid liposarcoma, and
pleomorphic liposarcoma (Jo & Fletcher, 2014).
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While these subtypes represent a different kind of liposarcoma, each disease is
heterogeneous. For example, well-differentiated liposarcoma is considered a low-grade neoplasm
with a small probability of metastasis (Patil & Chamberlain, 2013). Since the well-differentiated
subtype of liposarcoma is more likely to stay local than other forms of liposarcoma, surgery is
often recommended as the primary treatment option (Patil & Chamberlain, 2013). Whereas
myxoid liposarcoma, which is defined as a lipomatous mass with myxoid stroma, is
radioresponsive and radiosensitive, research suggests a higher response rate with a treatment
combination of radiation and chemotherapy (Chowdhry et al., 2018).
Mutations of recurrent well-differentiated tumors can sometimes result in a change in
tumor histology. For example, dedifferentiated tumors contain patterns of both well-differentiated
and other higher grade nonlipogenic elements (Wang & Lucas, 2018). Although current estimates
of more aggressive dedifferentiated nodules arising from recurrent well-differentiated tumors are
only around 10% (Wang & Lucas, 2018), their aggressiveness makes this type of liposarcoma
more deadly (Wang & Lucas, 2018). Research shows that current five-year survival rates for
dedifferentiated tumors are as low as 20% to 40% (Wang & Lucas, 2018). These statistics are not
surprising given that dedifferentiated tumors are often higher grade, heterogeneous in nature, and
have limited response to current therapy (Wang & Lucas, 2018; Dalal, Antonescu, & Singer,
2008).
2.4

Liposarcoma and Tumor Site
Tumor location can also influence the course of treatment and survival prognosis. For

tumors found on the extremities, the primary therapy is surgery followed by adjuvant radiation or
chemotherapy (Vos et al., 2019). It has established that patients with extremity well-differentiated
liposarcoma have a good prognosis (Vos et al., 2019; Gatta et al., 2017). For example, 191 patients
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from a study led by Vos et al. (2019), who were diagnosed with well-differentiated liposarcoma
and treated surgically followed by radiotherapy, had a 5-year survival rate of 98%. However, not
all patients fare so well. Patients with tumors located in areas where excision is no longer possible,
such as retroperitoneum, have lower survival rates (Schwartz et al., 2019). This is because tumors
in the retroperitoneum are often larger in size and asymptomatic until they become too big for
resection (Schwartz et al., 2019).

Studies have confirmed that patients diagnosed with

retroperitoneal tumors indeed have low survival rates (Tseng et al., 2011; Smith et al., 2012;
Swartz et al., 2019). Hence, retroperitoneal tumors have fewer treatment options and a poorer
prognosis.
Tumor site is not the only factor taken into consideration for therapy. Patient and tumor
characteristics such as age, comorbidities, tumor grade, size and histology all play a role in
treatment decisions (Vos et al., 2008). As mentioned above, histology is one of the most important
factors influencing treatment and, ultimately survival. For those diagnosed with dedifferentiated
tumors of the retroperitoneum, even if surgical resection is a viable treatment option, recurrence
occurs in over 80% of the patients, with 30% to metastatic sites (Dalal, Antonescu, & Singer,
2008). Thus, the limited treatment options for those with recurrent liposarcoma in the
retroperitoneum can partially explain this poor outcome.
2.5

Summary of literature review
Highlights from the literature review of previous studies include:
•

Rare diseases such as liposarcoma are understudied

•

There are no studies that have examined liposarcoma trends using national NPCR
datasets

•

Liposarcoma incident rates are twice as high for men than women
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•

Research shows that liposarcoma affects whites more than any other ethnicity

•

Liposarcoma histology often determines treatment options and survival rates

•

Tumor site also plays a role in survival prognosis.
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CHAPTER 3
MANUSCRIPT
INTRODUCTION
A rare disease, by definition, affects a small number of people. Ignored by the
pharmaceutical industry as well as epidemiological and clinical research, rare diseases have a
considerable impact on public health outcomes. The National Institutes of Health estimates that up
to 30 million people or 10 percent of the U.S. population have a rare disease (National Institutes
of Health, 2017). Globally, this translates to 400 million people (Global Genes, n.d.). While each
specific disease is considered rare, the sum of all rare diseases has a far-reaching impact on
population health. Limited treatment options, high costs of existing treatments, and frequent
misdiagnosis burden patients, physicians, and health systems (Ronicke, et al., 2019). Moreover,
the lack of knowledge about the risk factors for rare diseases makes their prevention unattainable.
Although some rare diseases are not fatal, rare cancers are. All of the above-mentioned
issues – misdiagnosis, limited treatment options, and lack of viable prevention measures – are
especially critical for rare cancers, making it one of the most dramatic unresolved public health
problems (Gatta et al., 2011; DeSantis, Kramer, & Jemal, 2017; Gatta et al., 2017). Populationbased research reveals the stark statistics of rare cancers. In Europe, incidence of rare cancers is
estimated as 108 cases per 100,000, or 22% of all new annual cancer diagnoses (Gatta et al., 2011).
Likewise, in the U.S., 20% of all new cancer diagnoses are considered rare (DeSantis, Kramer, &
Jemal, 2017). Emphasizing the gaps in research and treatment, the 5-year survival for rare cancers
is worse as compared to common cancers: 49% vs. 63% in Europe (Gatta et al., 2017), and in the
U.S., 55% vs. 75% among males and 60% vs. 74% among females (DeSantis, Kramer, & Jemal,
2017). Heterogeneity of rare cancers further complicates the development of evidence-based
guidelines of care. For example, even though sarcomas represent 1% of all adult malignant tumors,
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included in that 1%, are over 70 different subtypes (Mathoulin-Pelissier & Pritchard-Jones, 2019).
Randomized controlled trials for these distinct morphologies are often underpowered, leaving
many questions of treatment and care unanswered, thus, requiring new approaches.
Our interest in liposarcoma was motivated by the anxiety, desperation, and death of our
friends and relatives diagnosed with a rare cancer, liposarcoma, a cancer with limited treatment
options, and unknown risk factors. We conducted this research to elucidate the extent of
liposarcoma burden in the U.S. We believe that change is possible only when the attention of the
scientific community and public health advocates focuses on the problem of rare cancers, as it was
demonstrated by the HIV/AIDS advocacy movement. Their movement mobilized researchers and
the community to discover the causes and treatment for this initially rare disease (Fastercures and
HCM Strategists, n.d.). By this contribution, we hope to bring the problem of rare cancers,
specifically liposarcoma, to the attention of the scientific community.
Liposarcoma is a malignant mesenchymal tumor (Muratori et al., 2018), accounting for
almost 20% percent of all mesenchymal tumors (Barbetakis et al., 2007). It can be found anywhere
in the body, but most commonly is found in the extremities and retroperitoneum (Barbetakis et al.,
2007). Population-based research of liposarcoma in the U.S. is limited. Previously published
analyses focused on histology (Wu, Qian, & Jin, 2019), targeted therapy (Tseng et al., 201), and
the relationship between survival and tumor location or treatment (Smith et al., 2012; Gerry, Fox,
Spruill, & Lentsch, 2014). Our analysis fills the gaps in the literature by not only including the
latest and most comprehensive data available but also examining liposarcoma incidence trends
over time.
In this study, we used two publicly available data sources. The Surveillance, Epidemiology,
and End Result (SEER) program is the most frequently used population-based cancer incidence
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data. The updated dataset provides information on cancer surveillance from 18 registries across
the U.S (Centers for Disease Control and Prevention, n.d.; SEER.cancer.gov, n.d.). However, a
new publicly released data source called National Program of Cancer Registries (NPCR) has
recently become available. This registry covers 46 states and 97% of the U.S. population (Centers
for Disease Control and Prevention, n.d). Combined, the SEER and NPCR datasets (CNPCR)
provide cancer statistics covering 100% of the U.S. population (Centers for Disease Control and
Prevention, n.d).

While both data sources provide useful information, each has specific

advantages. Although SEER represents ~27.8% of the population, it contains more detailed
information on tumor characteristics and estimates of survival. CNPCR, on the other hand, has
broader representation of cancer in the U.S., but limited information on tumor characteristics and
no information on survival. Our analysis begins by examining liposarcoma distribution by
demographic and tumor characteristics as well as estimates of age-adjusted incidence rates. We
then present age-specific incidence rates and examine time trends of liposarcoma. Next, we
compare the nationwide estimates (CNPCR) with those derived from the SEER. Lastly, using
SEER, we delve further into liposarcoma tumor characteristics by examining distribution of cases
by grade, size, stage, and survival.
METHODS
Incident cases of liposarcoma between 2001 and 2016 were identified using SEER 18
(November 2018) and the combined NPCR (November 2018) and SEER registry (hereafter
referred as CNPCR). Cases were defined by the International Classification for Oncology, 3rd
edition (ICD-0-3), codes 8850-8860 with age at diagnoses ≥ 18 years.15 Annual incidence rates
were calculated using SEER*Stat software (version 8.3.5) (Surveillance Research Program,
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National Cancer Institute, n.d). All rates were expressed per 100,000 person-years and ageadjusted to the 2000 U.S. standard population.

Variables available from SEER and CNPCR datasets
In 2013, the World Health Organization (WHO) issued reclassification of soft tissue
sarcomas which redefined liposarcoma into four major histological subgroups: atypical lipomatous
tumors/well-differentiated liposarcoma, dedifferentiated liposarcoma, myxoid liposarcoma, and
pleomorphic liposarcoma (Jo & Fletcher, 2014). This new classification system not only takes
into consideration the distinct morphology, but also the genetic make-up of the tumor, helping
researchers to determine patterns of disease and treatment options (Jo & Fletcher, 2014; Blay,
2018). Following the 2013 WHO reclassification (Jo & Fletcher, 2014) liposarcoma histology was
categorized as well-differentiated, myxoid, pleomorphic, dedifferentiated and other (round cell,
mixed, angiomyoliposarcoma, fibroblastic and not otherwise specified).

Tumor site was

categorized as retroperitoneal, extremities, or other. Race was categorized as white, black, or other
(American Indian/Alaska Native, Asian or Pacific Islander, Hispanic). Age-specific rates were
calculated for the following age groups: < 35, 35-44, 45-54, 55-64, 65-74, 75-84, and 85 years and
older.

Variables available from SEER dataset
Histologic tumor grade was labeled as low (grade I) and high (grades II, III, and IV). Tumor
stage was defined as localized, regional/distant, and unknown. Given the limitation of SEER data
in 2016 (retroperitoneal data was not reported), the distribution of stage and frequency of
metastasis at diagnosis was described using data from 2001-2015. Relative 5-year survival
(proportion of observed cancer survivors to expected cancer-free survivors) was calculated using
SEER*stat software (Surveillance Research Program, National Cancer Institute, 2019). The 5-
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year relative survival estimates excluded patients with cancer were reported through autopsy or
death certificate.
Time trends
Time trends of liposarcoma age-adjusted incidence were examined using Joinpoint
regression modeling software, version 4.7 (Joinpoint Regression Program, 2018). Total percent
change (PC) for 2001-2016 and annual percent change (APC) were calculated for all cases and
stratified by gender, race, and site.
RESULTS
Our analyses identified 11,162 cases of liposarcoma from 2001-2016 in SEER, which
constituted 30% of liposarcoma cases identified by CNPCR (n = 37,499). Distribution of
liposarcoma by sex was similar in both SEER and CNPCR, with men accounting for approximately
60% of new cases. Liposarcoma was predominantly found in whites, accounting for 82%-86% of
all tumors (Table 1). The most common histological subtypes were well-differentiated tumors
(33% and 31%), followed by other (21% and 23%), dedifferentiated (20% in both), myxoid (19%
in both), and pleomorphic (7% and 8%) tumors in SEER and CNPCR, respectively. Tumors were
mostly found in the extremities (39%-41%) and retroperitoneum (21%-22%), with other areas of
the body accounting for 39% (Table 2). In general, both SEER and CNPCR showed similar
liposarcoma age-adjusted rates, with a slight overestimation by the SEER data. The overall ageadjusted incidence rates were estimated as 1.08 (95% CI, 1.06-1.10) and 1.01 (95% CI, 1.00-1.02)
per 100,000 person-years, from SEER and CNPCR, respectively. The incidence rates were nearly
twice as high for males as compared to females, which were greatest among whites and lowest
among blacks (Table 1).
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When examined by tumor characteristics (Table 2), the highest rates were found for welldifferentiated tumors (0.31-0.35 cases per 100,000 person-years).

Rates of myxoid,

dedifferentiated, and the category of other tumors ranged between 0.19-0.23 cases per 100,000
person-years, whereas pleomorphic tumors had the lowest incidence rate (0.08 cases per 100,000
person-years). Compared to CNPCR, SEER also slightly overestimated the rates for tumors found
in the extremities, in sites labeled other and in the retroperitoneum.
Age-Specific rates- SEER and CNPCR
As with many other cancers, liposarcoma incidence rates increased with age (Figure 1).
The CNPCR data show an increase in incidence among males until age 80-84 years with the peak
rate of 4.36 (95% CI, 4.14-4.36) cases per 100,000 person-years. The SEER data show a similar
pattern with slightly earlier peak at 75-84 years, estimated as 4.95 (95% CI, 4.58-5.35) cases per
100,000 person-years (Figure 1). Compared to the CNPCR, SEER age-specific rates consistently
overestimated liposarcoma incidence among males, with the greatest differences between 75-80
years. Liposarcoma rates for women reached a peak at an earlier age interval in CNPCR (75-79
years) as compared to SEER (80-84 years); however, the difference in age-specific rates at the
peak (and overall) was not as pronounced between the two data sources, with the CNPCR estimate
of 1.89 (95% CI, 1.79-2.00) and the SEER estimate of 1.97 (1.74-2.22) cases per 100,000 personyears (Figure 1).
Time trends- SEER and CNPCR
The most alarming finding was the increasing rates of liposarcoma from 2001-2016
identified by both SEER and CNPCR (Table 3). Liposarcoma rates are on a continuous upward
trend (Supplemental Figure 1). The annual increase of liposarcoma incidence (APC) was estimated
as 1.77% (95% CI, 1.21-2.33) and 1.43% (95% CI, 1.12-1.74) and the overall increase (PC) of
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liposarcoma was estimated as 27.2% and 19.0 % by SEER and CNPCR, respectively. The sexdifferences in time trends were under-estimated by SEER, with males showing 1.3-fold greater
APC, whereas CNPCR showed almost twice greater APC in males – the demographic group that
is most affected by liposarcoma (Table 3). Stratification by race revealed the fastest growing
incidence among those categorized as other, with APCs of 2.68% (95% CI, 1.69-3.68) and 3.16%
(1.74, 4.60) estimated from CNPCR and SEER, respectively. Among whites, the increase in
incidence was 1.6-fold greater as compared to blacks, as estimated from CNPCR (Table 3).
Stratification by tumor site revealed that retroperitoneal and tumors categorized as other increased
approximately by 2% a year, whereas tumors arising in extremities increased at a much slower
rate, APC=0.58% (95% CI, 0.18-0.98), as estimated from CNPCR (Table 3). Comparing time
trend estimates derived from SEER and CNPCR, it is clear that overestimation of the SEERderived trends was fairly consistent except for the analysis of retroperitoneal tumors: APC was
higher as estimated by CNPCR [1.94% (95% CI, 1.40-2.49)] than by SEER [1.36% (95% CI, 0.342.40)].
Distribution of liposarcoma by grade, size, stage – SEER
Table 4 depicts the distribution of liposarcoma cases by tumor grade, size, and stage. This
table shows that a considerable proportion of tumors (10-19%) had missing data. More tumors
were considered low grade (46%), larger in size, ≥ 10 cm (58%), and diagnosed at an earlier stage
(59%). Distributions of tumor grade did not differ by sex, race, and site. However, our analysis
uncovered a sharp difference in size and stage of the tumors at different sites. Retroperitoneal
tumors are diagnosed as larger in size, ≥ 10 cm (75%), and at a more advanced (i.e.,
regional/distant) stage (45%).
Survival Analysis – SEER
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Overall, 5-year relative survival did not differ by sex and race (Table 5). As expected,
well-differentiated tumors predicted better survival [95.5% (95% CI, 93.6-96.9)], while
pleomorphic [64.1% (95% CI, 59.1-68.7)] and dedifferentiated [57.2% (95% CI, 54.0-60.3)]
indicated poorer survival. There was also a sharp difference in survival by site and grade. Tumors
located on the extremities had the greatest 5-year survival rates at 89.9% (95% CI, 88.4-91.3),
while retroperitoneal tumors were the deadliest [63.9% (95% CI, 61.0-66.7)]. As expected, those
diagnosed with low grade tumors survived longer [94.2% (95% CI, 92.7-95.4)] than those with
tumors considered high-grade [67.2% (95% CI, 65.1-69.1)].
DISCUSSION
This comprehensive analysis of liposarcoma includes the theoretically representative
samples of cancer cases (SEER) and the entire U.S. population (CNPCR). Whereas
generalizability of SEER data has been previously questioned (Nattinger, McAuliffe, & Schapira,
1997; Kuo & Mobley, 2016; Pedersen et al., 2019) a direct comparison of cancer rates and time
trends between SEER and the nationwide data (to the best of our knowledge) has not been
published. Such comparison is especially meaningful for rare cancers because the nationwide data
with a larger sample size provide a priori more precise estimates. Thus, one of our main objectives
was to derive and compare estimates from the latest data available from SEER and CNPCR. We
found reasonably similar estimates of liposarcoma incidence (for all cases) and time trends by
examining both datasets, with the SEER-derived estimates being slightly greater as compared to
the national data. The subgroup analysis revealed that the SEER-CNPCR differences in incidence
estimates were the most pronounced among males aged 60 and older, as demonstrated by the agespecific rates (Figure 1). Such an apparent overestimation of liposarcoma rates was not observed
among females (Figure 1). Older males account for the majority of liposarcoma tumors; thus, such

19

sex-age difference most likely drives the observed over-estimation of liposarcoma incidence by
SEER as presented in Tables 1 and 2.
The age-pattern of incidence observed presented a typical (Pedersen et al., 2019) increase
followed by a plateau and a decrease at very old age (Figure 1). After age 75-80, cancer incidence
is expected to decrease (Harding, Pompei, Lee, & Wilson, 2008); this may reflect increased cellular
senescence accompanied by suppression of cellular proliferation – the processes that should slow
tumor growth (Harding, Pompei, Lee, & Wilson, 2008). Alternatively, the drop in liposarcoma
(or other cancers) incidence at older age reflects poorer cancer detection in the older population
(Pedersen et al, 2019).
Since previously published studies focused on specific liposarcoma subtypes, there is no
direct comparison for our analysis of liposarcoma demographic, histological subtypes, and tumor
site distribution (Wu, Qian, & Jin, 2019). Indirectly, our data can be compared to a study of
liposarcoma that examines head and neck to other sites (Gerry, Fox, Spruill, & Lentsch, 2014).
Similar to this study, we found (bold) the majority of liposarcoma cases were male (60% vs. 59%),
white (86% vs. 82%) and well-differentiated (31% vs. 33%). Likewise, the National Cancer
Intelligence Network (NCIN) in the U.K. found twice greater liposarcoma rates among males vs.
females (National Cancer Intelligence Network, 2013).
Limited information has been published about liposarcoma time trends. The NCIN reported
that liposarcoma incidence in England from 1985 to 2009 had increased.26 These results are
consistent with our nationwide findings of rising liposarcoma rates in both sexes (Table 3,
Supplemental Figure 1). Thus, males not only have a greater risk of liposarcoma, but the incidence
among males increased at a faster rate. The fact that the rates are increasing so quickly in the
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subgroup with the greatest risk (males) emphasizes the urgency to better understand the risk factors
underlying such time trends.
Comparing time-trends derived from SEER and CNPCR, we found the greatest difference
of APC among blacks; specifically, SEER overestimated APC by almost twice as compared to
CNPCR for this racial group (Table 3). Thus, nationwide data are particularly important when
studying rare cancers among minority subgroups. When stratified by tumor location, the time
trends were highly overestimated by SEER for the tumors located in extremities, the least deadly
liposarcoma (89.9% survival), whereas for the deadliest tumor – retroperitoneal (63.9% survival)
– the SEER estimates were lower (Table 3). Overall, our analysis clearly demonstrates that
nationwide data are crucial in deriving a realistic picture of the trends in rare cancers.
Consistent with published results (Smith et al., 2012), the estimates of 5-year survival did
not differ between men and women (Table 5). Smith et al. showed no sex differences among welldifferentiated liposarcoma in the overall and disease-specific survival (2012). However, another
study, which examined survival among patients with extremity myxoid liposarcomas, showed
males as being a negative survival predictor (Wu, Qian, & Jin, 2019). For all cancer types overall,
the increased cancer risk and poor survival among males has been established by population-based
data (Radkiewicz, Johansson, Dickman, Lambe, & Edgren, 2017; Afshar, et al., 2018; Ellison,
2016). Thus, our findings of similar survival among males and females must be confirmed with
the more recent data when it becomes available.
Liposarcoma histology also influences survival prognosis. Histological features such as
differences in patterns of reoccurrence, metastatic risk, and grade, all influence survival (Tseng et
al., 2011; Smith et al., 2012). Our data showed well-differentiated histology as the most common
liposarcoma sub-type (33.04%) with the highest 5-year survival of 95.5% (Tables 2 and 5). In
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general, well-differentiated liposarcoma has a low probability of metastasis, and therefore,
treatment options such as marginal excision will often yield good results (Wang & Lucas, 2018).
However, well-differentiated tumors are also known for having a high rate of local recurrence
(Wang & Lucas, 2018). Patients with tumors located in areas where excision is no longer possible,
such as retroperitoneum, have lower survival (63.9%). Tumors in the retroperitoneum are often
larger in size and asymptomatic until they become too big for resection (Schwartz et al., 2019).
Hence, retroperitoneal tumors have fewer treatment options and a poorer prognosis. In agreement
with published results (Tseng et al., 2011; Smith et al., 2012; Schwartz et al., 2019) our analysis
confirms that patients diagnosed with retroperitoneal tumors indeed have the lowest survival rates
(Table 5).
Mutations of recurrent well-differentiated tumors can sometimes result in a change in
tumor histology. For example, dedifferentiated tumors contain patterns of both well-differentiated
and other higher grade nonlipogenic elements (Wang & Lucas, 2018). Current estimations of more
aggressive dedifferentiated nodules arising from recurrent well-differentiated tumors are around
10% (Wang & Lucas, 2018). Five-year survival rates for dedifferentiated tumors can be as low as
20% to 40% (Wang & Lucas, 2018).

In our data, the 5-year survival was higher, with

approximately 58% for the dedifferentiated sub-type, however, compared to the other histological
types of liposarcoma where survival ranges from 96% (well-differentiated) to 64% (pleomorphic),
dedifferentiated tumors are the most deadly. These statistics are not surprising given that
dedifferentiated tumors are often higher grade, heterogeneous in nature, and have limited response
to current therapy (Wang & Lucas, 2018; Dalal, Antonscu, & Singer, 2008). For those diagnosed
with dedifferentiated tumors of the retroperitoneum, even if surgical resection is a viable treatment
option, recurrence occurs in over 80% of the patients, with 30% to metastatic sites (Dalal,
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Antonescu, & Singer, 2008). Thus, the limited treatment options for those with recurrent
liposarcoma in the retroperitoneum can partially explain this poor outcome.
CONCLUSIONS
Whereas the U.S. is winning the war on cancer overall, not all population subgroups and
cancer patients benefit from the improvements in cancer control and prevention (Siegel, Miller, &
Jemal, 2019). Patients with rare cancers are at a disadvantage. We provide comprehensive
descriptive epidemiology estimates for the understudied rare cancer, liposarcoma. These findings
will serve as a reference for current liposarcoma research; however, it is important for future
research to periodically update these estimates as data become available. Our findings emphasize
the importance of nationwide data in studying rare cancers such as liposarcoma (Lyu et al., 2019).
Currently, SEER data have more tumor (extent of disease such as tumor size, metastasis, etc.) and
patient characteristics (place of residence at the time of diagnosis, time to death) as compared to
the publicly available NPCR data. In order to make progress in understanding liposarcoma etiology
and track progress in treatment, future studies of rare cancers must be based on the nationwide
data with the inclusion of as many tumor and patient characteristics as possible. Finally, we
demonstrated that liposarcoma incidence is rising, suggesting that non-genetic modifiable risk
factors may play a role in the etiology of this malignancy. Identification of such risk factors is
necessary for the development of prevention strategies.
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Table 4.1 Liposarcoma cases and age-adjusted incidence rates by demographic
characteristics, 2001-2016
SEER
CNPCR
Incidence Rate,
Incidence Rate,
Cases per 100,000 pCases per 100,000 pCount (%)
Count (%)
years
years
(95% CI)
(95% CI)
All cases
11,162 (100)
1.08 (1.06,1.10)
37,499 (100)
1.01 (1.00, 1.02)
Sex
22,681
Male (ref)
6,803 (60.95)
1.44 (1.41, 1.48)
1.33 (1.31, 1.35)
(60.48)
14,818
Female
4,359 (39.05)
0.79 (0.77, 0.82)*
0.75 (0.74, 0.77)*
(39.52)
Race
32,186
White (ref) 9,198 (82.40)
1.13 (1.10, 1.15)
1.04 (1.03, 1.05)
(85.83)
Black
922 (8.26)
0.85 (0.79, 0.91)*
3,235 (8.63)
0.81 (0.78, 0.84)*
Other
1,042 (9.34)
0.95 (0.89, 1.01)*
2,078 (5.54)
1.03 (0.99, 1.08)
* Rate significantly (p<0.05) different when compared to the reference category
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Table 4.2 Liposarcoma cases and age-adjusted incidence rates by tumor histology and site, 20012016
SEER
CNPCR
Incidence Rate,
Incidence Rate,
Count (%)
Cases per 100,000
Count (%)
Cases per 100,000 p-years
p-years (95% CI)
(95% CI)
Histological type
Well-differentiated
3,688
11,629
0.35 (0.34, 0.37)
0.31 (0.30, 0.32)
(ref)
(33.04)
(31.01)
Myxoid
2,094
0.21 (0.20, 0.22)* 6,938 (18.50)
0.19 (0.19, 0.20)*
(18.76)
Pleomorphic
818 (7.33)
0.08 (0.07, 0.09)*
2,922 (7.79)
0.08 (0.08, 0.08)*
Dedifferentiated
2,193
0.21 (0.20, 0.22)* 7,558 (20.16)
0.20 (0.20, 0.21)*
(19.65)
Other#
2,369
0.23 (0.22, 0.24)* 8,452 (22.54)
0.23 (0.22, 0.23)*
(21.22)
Tumor site
2,323
Retroperitoneal
0.22 (0.21, 0.23)* 8,203 (21.88)
0.22 (0.21, 0.22)*
(20.81)
4,531
14,768
Extremities (ref)
0.44 (0.43, 0.45)
0.40 (0.40, 0.41)
(40.59)
(39.38)
4,308
14,528
Other sites
0.42 (0.41, 0.43)
0.39 (0.38, 0.40)
(38.60)
(38.74)
* Rate significantly (p<0.05) different when compared to the reference category
#
Includes round cell, mixed, angiomyoliposarcoma, fibroblastic and not otherwise specified
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Table 4.3 Time trends in liposarcoma, 2001-2016
SEER
Total % change
Annual %
change
(95% CI)
All cases
27.16
1.77 (1.21, 2.33)
Sex
Males
31.53
1.87 (1.37, 2.37)
Females
19.95
1.47 (0.68, 2.27)
Race/ethnicity
Whites
26.14
1.69 (1.01, 2.37)
Blacks
14.01
1.62 (0.00, 3.29)
Other
48.13
3.16 (1.74, 4.60)
Site
Extremities
2.80
1.07 (0.29, 1.87)
Retroperitoneal
28.22
1.36 (0.34, 2.40)
Other
64.23
2.69 (1.85, 3.53)

CNPCR
Total % change
Annual %
change
(95% CI)
18.95
1.43 (1.12, 1.74)
21.77
12.57

1.67 (1.34, 2.00)
0.89 (0.51, 1.26)

19.33
4.38
30.35

1.40 (1.06, 1.74)
0.88 (0.02, 1.76)
2.68 (1.69, 3.68)

2.89
26.03
34.41

0.58 (0.18, 0.98)
1.94 (1.40, 2.49)
2.02 (1.57, 2.48)
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Table 4.4 Distribution of liposarcoma tumors by grade, size, and stage: SEER, 2001 – 20016
Grade, %
Size, %
Stage, %
Low
High
Unknown
<10
≥10cm Unknown Localized* Regional/ Unknown*
(I)
(II-IV)
cm
Distant*
All cases
45.9
38.7
15.4
31.4
57.5
11.1
59.3
27.5
13.2
Sex
Males
44.9
40.4
14.7
32.1
56.4
11.6
59.5
26.9
13.5
Females
47.4
36.0
16.6
30.3
59.3
10.4
58.8
28.5
12.7
Race
White
45.7
38.9
15.4
31.2
57.7
11.1
59.1
28.1
12.7
Black
44.1
37.1
18.8
33.6
55.4
10.8
62.7
24.4
12.9
Other
48.9
38.0
13.1
30.6
57.6
11.8
57.4
25.0
17.6
Site
44.3
40.9
14.8
16.3
74.7
9.0
42.3
44.7
13.0
Retroperitoneal
Extremities
47.1
38.0
15.0
34.3
57.2
8.5
71.0
18.4
10.7
Other sites
45.5
38.2
16.3
36.3
48.6
15.1
56.1
27.9
15.9
*Due to the lack of reporting of certain cancer variables, stage was tabulated using SEER Historic Stage
A (2001-2015).
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Table 4.5 Five-year survival of patients with liposarcoma: SEER, 2001-2016
Relative Survival, %
All cases
79.8 (78.6, 80.9)
Sex
Male
79.0 (77.5, 80.4)
Female
81.0 (79.2, 82.6)
Race
White
79.5 (78.2, 80.8)
Black
80.9 (76.8, 84.3)
Other
80.9 (77.1, 84.1)
Histological type
Well-differentiated
95.5 (93.6, 96.9)
Myxoid
85.7 (83.5, 87.7)
Pleomorphic
64.1 (59.1, 68.7)
Dedifferentiated
57.2 (54.0, 60.3)
Other
75.0 (72.4, 77.4)
Site
Retroperitoneal
63.9 (61.0, 66.7)
Extremities
89.9 (88.4, 91.3)
Other
76.7 (74.7, 78.6)
Grade
Low Grade (I)
94.2 (92.7, 95.4)
High Grade (II-IV)
67.2 (65.1, 69.1)
Unknown
67.6 (64.4,70.6)
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Figure 2.1

Age-specific incidence rates of liposarcoma among males and females as
estimated from SEER and CNPCR data for the period of 2001-2016

29

Figure 2.2

Time trends in liposarcoma incidence by sex: CNPCR data, 2001-2016
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Figure 2.3

Time trends in liposarcoma incidence by race: CNPCR data, 2001-2016
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Figure 2.4

Time trends in liposarcoma incidence by site: CNPCR data, 2001-2016
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